Cargando…

Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment

INTRODUCTION: There is no effective treatment plan for coronavirus disease 2019 (COVID-19). We employed a combination of Chinese and Western medicine treatment for some COVID-19 inpatients. METHODS: This study was a prospective cohort study that observed non-critical COVID-19 inpatients. The differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Yongxin, Fang, Jiayang, Liu, Yunzhu, Gao, Yidong, Lin, Weizhi, Hao, Dongdong, Zhang, Xing, Zhang, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675424/
https://www.ncbi.nlm.nih.gov/pubmed/36411815
http://dx.doi.org/10.2147/IJGM.S391024
_version_ 1784833369208520704
author Yi, Yongxin
Fang, Jiayang
Liu, Yunzhu
Gao, Yidong
Lin, Weizhi
Hao, Dongdong
Zhang, Xing
Zhang, Min
author_facet Yi, Yongxin
Fang, Jiayang
Liu, Yunzhu
Gao, Yidong
Lin, Weizhi
Hao, Dongdong
Zhang, Xing
Zhang, Min
author_sort Yi, Yongxin
collection PubMed
description INTRODUCTION: There is no effective treatment plan for coronavirus disease 2019 (COVID-19). We employed a combination of Chinese and Western medicine treatment for some COVID-19 inpatients. METHODS: This study was a prospective cohort study that observed non-critical COVID-19 inpatients. The differences will be observed in the time from admission to two consecutive 2019-nCoV nucleic acid test negatives and the Visual Analog Scale (VAS) score between the two groups. RESULTS: A total of 254 confirmed COVID-19 patients were included in this study. The median time from the admission to two consecutive negative nucleic acid tests was 14 days for the integrated Chinese and Western Medicine (ICWM) group, while the Western Medicine (WM) group was 16 days. Besides, the median VAS score of the ICWM group was 0, which was an average decrease of 2 points compared to the time of admission. CONCLUSION: For non-critical COVID-19 patients, it was safe and have more benefits to add traditional Chinese medicine decoction based on WM treatment.
format Online
Article
Text
id pubmed-9675424
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96754242022-11-20 Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment Yi, Yongxin Fang, Jiayang Liu, Yunzhu Gao, Yidong Lin, Weizhi Hao, Dongdong Zhang, Xing Zhang, Min Int J Gen Med Original Research INTRODUCTION: There is no effective treatment plan for coronavirus disease 2019 (COVID-19). We employed a combination of Chinese and Western medicine treatment for some COVID-19 inpatients. METHODS: This study was a prospective cohort study that observed non-critical COVID-19 inpatients. The differences will be observed in the time from admission to two consecutive 2019-nCoV nucleic acid test negatives and the Visual Analog Scale (VAS) score between the two groups. RESULTS: A total of 254 confirmed COVID-19 patients were included in this study. The median time from the admission to two consecutive negative nucleic acid tests was 14 days for the integrated Chinese and Western Medicine (ICWM) group, while the Western Medicine (WM) group was 16 days. Besides, the median VAS score of the ICWM group was 0, which was an average decrease of 2 points compared to the time of admission. CONCLUSION: For non-critical COVID-19 patients, it was safe and have more benefits to add traditional Chinese medicine decoction based on WM treatment. Dove 2022-11-15 /pmc/articles/PMC9675424/ /pubmed/36411815 http://dx.doi.org/10.2147/IJGM.S391024 Text en © 2022 Yi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yi, Yongxin
Fang, Jiayang
Liu, Yunzhu
Gao, Yidong
Lin, Weizhi
Hao, Dongdong
Zhang, Xing
Zhang, Min
Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment
title Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment
title_full Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment
title_fullStr Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment
title_full_unstemmed Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment
title_short Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment
title_sort clinical characteristics of 254 covid-19 inpatients in yichang, hubei, china, and efficacy of integrated chinese and western medicine treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675424/
https://www.ncbi.nlm.nih.gov/pubmed/36411815
http://dx.doi.org/10.2147/IJGM.S391024
work_keys_str_mv AT yiyongxin clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment
AT fangjiayang clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment
AT liuyunzhu clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment
AT gaoyidong clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment
AT linweizhi clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment
AT haodongdong clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment
AT zhangxing clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment
AT zhangmin clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment